Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
収録刊行物
-
- The Lancet
-
The Lancet 400 (10358), 1103-1116, 2022-10
Elsevier BV